Monographie - Amsacrine - Stabilis 4.0

Last update :
19/11/2024

Anticancer drug

Amsacrine

injection

Stability in solutions

Stability of mixtures

Factors which affect stability

Compatibility

Route of administration

References

pdf

Chemical structure

Tradename

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Amekrin	Denmark, Finland, Norway, Sweden
Amsa PD	Canada
Amsalyo	France
Amsidine	Australia, Belgium, Italy, Netherlands
Amsidyl	Germany, Switzerland

References

injection

References : Amsacrine

	Type	Publication
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
253	Journal	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
829	Journal	Cartwright-Shamoon JM, McElnay JC, D'Arcy PF. Examination of sorption and photodegradation of amsacrine during storage in intravenous burette administration sets. Int J Pharm 1988 ; 42: 41-46.
3523	Manufacturer	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3576	Manufacturer	Amsacrine (Amsalyo®) - Résumé des caractéristiques du produit Prostrakan 2012
3595	Manufacturer	Aciclovir - Summary of Product Characteristics Hospira 2009
3745	Journal	Kuenhle C, Moore Sodium chloride residue provides potential for drug incompatibiities. Am J Hosp Pharm 1979 ; 36: 881.

Mentions Légales